Dapagliflozin once daily plus exenatide once weekly in obese adults without diabetes: Sustained reductions in body weight, glycaemia and blood pressure over 1 year.
Per LundkvistMaria J PereiraPetros KatsogiannosC David SjöströmEva JohnssonJan W ErikssonPublished in: Diabetes, obesity & metabolism (2017)
Dapagliflozin + exenatide dual therapy produced sustained reductions in body weight, prediabetes and SBP over 52 weeks and was well tolerated in obese adults without diabetes.